We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Accelr8 Announces New Management

Accelr8 Announces New Management

Accelr8 Announces New Management

Accelr8 Announces New Management

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Accelr8 Announces New Management"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Accelr8 Technology Corporation has announced the appointment of Lawrence Mehren as President and Chief Executive Officer and a member of the Board of Directors.

Most recently, Mr. Mehren was Head of Global Business of Ventana Medical Systems and Roche Tissue Diagnostics, managing its four business units, as well as Spring Biosciences, and mtm laboratories.

From 2007 until 2010 he held various global leadership positions with Ventana including Senior Vice President, Emerging Businesses, and Chief Financial Officer.

Previously, he was Managing Director, Partner and head of P&M Corporate Finance’s life sciences practice.

Prior to his tenure at P&M, Mr. Mehren worked in management positions with Gale Group, a division of The Thomson Corporation, as well as Merrill Lynch.

Mr. Mehren holds a B.A. from the University of Arizona and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management.

“We are fortunate to have someone of Larry Mehren’s caliber and experience to lead Accelr8” said John Patience, Chairman of the Board.

Patience continued, “Larry’s vision and proven track record of execution in the global diagnostics industry will allow us to fully realize the potential of Accelr8.”

“I am excited to be joining Accelr8 at such a pivotal time,” said Mehren.

“The company has created a unique solution to a tremendous unmet need. I look forward to advancing the development and commercialization of this transformational technology.”